This report on global glioblastoma multiforme market studies various drugs used for treatment of glioblastoma along with pipeline analysis of upcoming potential drugs.  Glioblastoma multiforme is the most common and most aggressive cancer that begins within the brain. According to Brain Tumour Foundation of Canada, The incidence of glioblastoma multiforme (GBM) is 2 to 3 per 100,000 people in the United States and Europe. GBM accounts for 12 to 15% of all intracranial tumours and 50 to 60 per cent of astrocytic tumours.

For the purpose of this study, the various drugs studied include bevacizumab, temozolomide, and carmustine. Market size estimates and forecast for these segments for the period 2013 to 2029 are provided in terms of USD Mn along with the respective CAGRs for the period 2021 to 2029, considering 2020 as the base year.

The pipeline analysis for glioblastoma multiforme market comprises projected market sales of Phase III drugs estimated till 2029. The phase III drugs included in the pipeline analysis are TRC-105, VB-111, TOCA 511, DCVax-Brain, Rindopepimut (CDX-110), and others. The report also covers qualitative information associated with the drugs under phase II and I of the clinical trials.

The geographic segmentation of the global glioblastoma multiforme market is performed for the regions North America, Europe, Asia Pacific and Rest of the World markets. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecast for these segments for the period 2013 to 2029 are provided in terms of USD Mn along with the respective CAGRs for the period 2021 to 2029, considering 2020 as the base year. 

According to American Association of Neurological Surgeons (AANS), The National Cancer Institute estimates that 22,850 adults (12,630 men and 10,280 women) were diagnosed with brain and other nervous system cancer in 2020. It also estimates that in 2020, 15,320 of these diagnoses resulted in death. Glioblastoma multiforme (GBM) has an incidence of two to three per 100,000 adults per year, and accounts for 52% of all primary brain tumors. Overall, GBM accounts for about 17% of all tumors of the brain (primary and metastatic). It is categorized as one of the orphan diseases with high mortality rate.

In base year 2020, temozolomide accounted for the largest market share of the global glioblastoma multiforme market. The key advantages possessed by temozolomide are delayed progression without impacting the quality of life and less adverse effects compared to other molecules. Medical practitioners suggest that, combination radiotherapy and temozolomide chemotherapy is currently the standard of care for most patients suffering from GBM. Temozolomide belongs to the class of alkylating agents; the mechanism of action comprises cell destruction initiated by abnormal methylations of DNA bases, and in particular the formation of O6-alkylguanine in DNA. The DNA repair enzyme -methylguanine-DNA methyltransferase (MGMT) antagonizes the genotoxic effects of alkylating agents and MGMT gene silencing through promoter methylation is a favorable prognostic marker, predicting benefits from this sort of chemotherapy in GBM. Thus, temozolomide is the first line therapy used for GBM treatment but ongoing research to enhance efficiency of bevacizumab in GBM treatment might affect the temozolomide market share in the near future.

In base year 2020, North America and Europe dominated the market with around 60% of the overall market share. The key factors assisting the growth of glioblastoma multiforme market in these regions are mounting support from government and non-government organizations to increase public awareness related to diagnosis and treatment of GBM and advanced healthcare infrastructure to boost the pipeline research in this market. Market experts suggest that, key GBM treatment drugs are initially approved in these regions as North American and European markets are the most lucrative pharmaceutical markets. The upcoming pipeline drugs are expected to play crucial role in the GBM market where early market entry and high drug prices would be the key factors that will boost the overall GBM market in North America and Europe initially. Asia-Pacific is expected to grow at a significant pace where Japan is observed as the leading market followed by China and India. India and China have a large low- and middle-income population; hence, demand for low cost treatments is high. However, in case of life threatening diseases such as GBM the scenario is different as the available treatments are limited and require higher cost.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Glioblastoma Multiforme market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Glioblastoma Multiforme market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Glioblastoma Multiforme market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Glioblastoma Multiforme market?
• Which is the largest regional market for Glioblastoma Multiforme market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Glioblastoma Multiforme market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Glioblastoma Multiforme market worldwide?